Expertise in
3
conditions

Arun A. Azad

246 Clayton Road, 
Melbourne, VIC, AU 
Expertise in
3
conditions
246 Clayton Road, 
Melbourne, VIC, AU 

Overview

Arun Azad practices practicing medicine in Melbourne, Australia.

Mr. Azad is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), NUT Carcinoma, Prostatectomy, and Nephrectomy.

He is actively involved in clinical research, co-authoring 222 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

246 Clayton Road, Melbourne, VIC 3168, Australia
Other Locations
Level 6 LTB, 145 Studley Rd, Heidelberg, VIC 3084, Australia
Level 6, 145-163 Studley Road, Heidelberg, VIC 3084, Australia
145-163 Studley Road, Heidelberg, VIC 3084, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Enrollment Status: Completed
Publish Date: August 28, 2026
Intervention Type: Drug, Radiation
Study Drug: Ipilimumab/Nivolumab
Study Phase: Phase 2
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Phase: Phase 3
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2025
Intervention Type: Radiation, Drug
Study Drug: Darolutamide
Study Phase: Phase 2
A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
Enrollment Status: Terminated
Publish Date: August 10, 2022
Intervention Type: Drug
Study Drugs: GSK525762, Abiraterone, Enzalutamide, Prednisone
Study Phase: Phase 1
A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: August 07, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

222 Total Publications

Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.
Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 31, 2026

Frequently Asked Questions about Arun A. Azad

Is Arun A. Azad a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Arun A. Azad is classified as an Elite expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Arun A. Azad participate in research or clinical trials?

Yes. Arun A. Azad has published 222 articles and abstracts on conditions like Prostate Cancer. You can view a list of Arun A. Azad's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Azad's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile